Key result
Sacubitril/valsartan's effects on renal function in patients with heart failure with preserved ejection fraction, with and without diabetes, are discussed in this editorial.
Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This is an editorial discussing the effects of sacubitril/valsartan on renal function in HFpEF patients with and without diabetes from the PARAGON-HF trial.
This article refers to 'Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF' by A. Peikert et al., published in this issue on pages xxx.
No takes yet. Share an insight, caveat, or question.
Voordes et al. (2022) studied this question. Sacubitril/valsartan's effects on renal function in patients with heart failure with preserved ejection fraction, with and without diabetes, are discussed in this editorial.
Synapse has enriched 10 related papers. Consider them for comparative context: